Miraculins Inc. (MOM:CA) News

News for Miraculins Inc. (MOM:CA)

Sector News | Topic News

Tue, Jun 04, 2013

5:05 PM

Miraculins Announces Grant of Options - Marketwired

5:05 PM

Miraculins Announces Grant of Options - Marketwired

Fri, Apr 26, 2013

5:14 PM

Miraculins Reports First Quarter Financial Results for Fiscal 2013 - Marketwired

5:14 PM

Miraculins Reports First Quarter Financial Results for Fiscal 2013 - Marketwired

Thu, Apr 18, 2013

11:02 AM

Miraculins Leads Future of Global Health Tech Innovation - Accesswire

Mon, Apr 15, 2013

7:00 AM

Miraculins Executes Term Sheet to Acquire the SCOUT DS(R) Non-Invasive Diabetes Screening Technology - Marketwired

7:00 AM

Miraculins Executes Term Sheet to Acquire the SCOUT DS(R) Non-Invasive Diabetes Screening Technology - Marketwired

Mon, Apr 08, 2013

7:00 AM

Miraculins Announces Closing of Private Placement Offering - Marketwired

7:00 AM

Miraculins Announces Closing of Private Placement Offering - Marketwired

Mon, Mar 25, 2013

3:40 PM

Miraculins Announces Private Placement Offering - Marketwired

3:39 PM

Miraculins Announces Private Placement Offering - Marketwired

Fri, Mar 15, 2013

8:18 AM

Miraculins Announces National Accreditation of Pharmacist Education Program on Cardiovascular Risk Assessment with Focus on Skin Cholesterol - Marketwired

8:18 AM

Miraculins Announces National Accreditation of Pharmacist Education Program on Cardiovascular Risk Assessment with Focus on Skin Cholesterol - Marketwired

Mon, Mar 11, 2013

7:00 AM

Miraculins to License Additional Preeclampsia Technology from Mount Sinai Hospital - Marketwired

7:00 AM

Miraculins to License Additional Preeclampsia Technology from Mount Sinai Hospital - Marketwired

Wed, Feb 27, 2013

7:00 AM

PreVu(R) Skin Cholesterol Clinics Rollout Nationally - Marketwired

7:00 AM

PreVu(R) Skin Cholesterol Clinics Rollout Nationally - Marketwired

Tue, Feb 19, 2013

7:00 AM

Miraculins Moves Closer to PreVu(R) Expansion in U.S. and UK/EU through Key Market Development Team Appointments - Marketwired

7:00 AM

Miraculins Moves Closer to PreVu(R) Expansion in U.S. and UK/EU through Key Market Development Team Appointments - Marketwired

Tue, Feb 12, 2013

7:00 AM

Miraculins Initiates Pilot Study to Measure Skin Cholesterol Levels in Patients Beginning Statin Therapy - Marketwired

7:00 AM

Miraculins Initiates Pilot Study to Measure Skin Cholesterol Levels in Patients Beginning Statin Therapy - Marketwired

Mon, Feb 04, 2013

7:00 AM

Miraculins Named Manitoba Life Science Company of the Year - Marketwired

7:00 AM

Miraculins Named Manitoba Life Science Company of the Year - Marketwired

Mon, Jan 28, 2013

7:00 AM

Miraculins Updates Market on 2013 Plans for PreVu(R) - Marketwired

7:00 AM

Miraculins Updates Market on 2013 Plans for PreVu(R) - Marketwired

<<

First

<

Prev

1 2 3

Next

>

Last

>>

Financial Market Data powered by QuoteMedia.com. All rights reserved. View the Terms of Use
NYSE/AMEX data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless indicated.
RT Realtime, EOD End Of Day, PD Previous Day. PW Previous Week.

All information displayed and available herein is on an "as is", "as available" basis and neither InvestorPoint.com nor any of its underlying service providers, information providers, licensors, employees, distributors or agents make any representations as to the suitability of our service or the materials for any purpose. The information is not intended for trading purposes or advice. We specifically disclaim any representations or warranties, express or implied, including, without limitation, any representations or warranties of merchantability or fitness for a particular purpose. InvestorPoint.com is not an investment adviser. We do not: (a) give investment advice, (b) advocate the purchase or sale of any security or investment and (c) provide, endorse or review any information or data contained herein. We do not guarantee the accuracy of the information and data supplied by information providers. We are not liable or responsible for the quality, accuracy or reliability of this information. You should always seek the assistance of a professional for investment advice.